The Current Ratio as of November 2024 (TTM) for Tekla Life Sciences Investors (HQL) is 0.20

According to Tekla Life Sciences Investors’s latest financial reports and current stock price. The company's current Current Ratio is 0.20. This represents a change of 99.31% compared to the average of 0.10 of the last 4 quarters.

Tekla Life Sciences Investors (HQL) Historical Current Ratio (quarterly & annually)

How has HQL Current Ratio performed in the past?

The mean historical Current Ratio of Tekla Life Sciences Investors over the last ten years is 2.55. The current 0.20 Current Ratio has changed 665.89% with respect to the historical average. Over the past ten years (40 quarters), HQL's Current Ratio was at its highest in in the December 2016 quarter at 51.59. The Current Ratio was at its lowest in in the September 2023 quarter at 0.

Tekla Life Sciences Investors (HQL) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Tekla Life Sciences Investors Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Tekla Life Sciences Investors (HQL) Average Current Ratio

How has HQL Current Ratio performed in the past?

The current Current Ratio of Tekla Life Sciences Investors (HQL) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Tekla Life Sciences Investors (HQL) Current Ratio vs. Peers

How is HQL’s Current Ratio compared to its peers?

Tekla Life Sciences Investors’s Current Ratio is greater than Tekla World Healthcare Fund (0), greater than Tekla Healthcare Opportunities Fund (0), greater than Royce Value Trust Inc. (0), greater than John Hancock Financial Opportunities Fund (0.07), less than Tekla Healthcare Investors (0.46), greater than Flaherty & Crumrine Dynamic Preferred and Income Fund Inc. (0), greater than Cohen & Steers Infrastructure Fund, Inc (0), less than Eaton Vance Tax-Advantaged Global Dividend Income Fund (1.89), less than BlackRock MuniYield Fund, Inc. (0.30), less than Eaton Vance Tax-Advantaged Dividend Income Fund (1.21), less than Eaton Vance Tax-Managed Buy-Write Income Fund (0.29), less than Nuveen California Select Tax-Free Income Portfolio (3.14), greater than Cohen & Steers REIT and Preferred Income Fund, Inc. (0.05), greater than XAI Octagon Floating Rate & Alternative Income Term Trust (0), greater than Nuveen Preferred and Income Term Fund (0), greater than First Trust Intermediate Duration Preferred & Income Fund (0), less than Flaherty & Crumrine Preferred Securities Income Fund Inc. (2.07), greater than Eaton Vance Risk-Managed Diversified Equity Income Fund (0),

Build a custom stock screener for Tekla Life Sciences Investors (HQL) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Tekla Life Sciences Investors using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Tekla Life Sciences Investors (HQL) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Tekla Life Sciences Investors or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.